[go: up one dir, main page]

CL2016000777A1 - Biomarcadores de cáncer y usos de los mismos - Google Patents

Biomarcadores de cáncer y usos de los mismos

Info

Publication number
CL2016000777A1
CL2016000777A1 CL2016000777A CL2016000777A CL2016000777A1 CL 2016000777 A1 CL2016000777 A1 CL 2016000777A1 CL 2016000777 A CL2016000777 A CL 2016000777A CL 2016000777 A CL2016000777 A CL 2016000777A CL 2016000777 A1 CL2016000777 A1 CL 2016000777A1
Authority
CL
Chile
Prior art keywords
cancer biomarkers
biomarkers
cancer
Prior art date
Application number
CL2016000777A
Other languages
English (en)
Inventor
Kinmei Leung
Sarah Batey
Haijun Sun
Robert Rowland
Original Assignee
F-Star Biotechnology Ltd
F-Star Biotechnologische Forschungs-Und Entw M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F-Star Biotechnology Ltd, F-Star Biotechnologische Forschungs-Und Entw M B H filed Critical F-Star Biotechnology Ltd
Publication of CL2016000777A1 publication Critical patent/CL2016000777A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2016000777A 2013-10-04 2016-04-04 Biomarcadores de cáncer y usos de los mismos CL2016000777A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1317622.7A GB201317622D0 (en) 2013-10-04 2013-10-04 Cancer biomarkers and uses thereof
PCT/GB2014/052994 WO2015049537A1 (en) 2013-10-04 2014-10-03 Cancer biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
CL2016000777A1 true CL2016000777A1 (es) 2017-02-17

Family

ID=49630223

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000777A CL2016000777A1 (es) 2013-10-04 2016-04-04 Biomarcadores de cáncer y usos de los mismos

Country Status (21)

Country Link
US (1) US20160289336A1 (es)
EP (1) EP3052647B1 (es)
JP (1) JP6449308B2 (es)
KR (1) KR20160092992A (es)
CN (1) CN105722997A (es)
AU (1) AU2014330942A1 (es)
BR (1) BR112016007348A2 (es)
CA (1) CA2925186A1 (es)
CL (1) CL2016000777A1 (es)
DK (1) DK3052647T3 (es)
EA (1) EA201690450A1 (es)
ES (1) ES2687783T3 (es)
GB (1) GB201317622D0 (es)
HK (1) HK1221746A1 (es)
HR (1) HRP20181566T1 (es)
IL (1) IL244510A0 (es)
LT (1) LT3052647T (es)
MX (1) MX2016004286A (es)
PE (1) PE20160950A1 (es)
SG (1) SG11201602605TA (es)
WO (1) WO2015049537A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1699826T1 (sl) 2005-01-05 2009-08-31 Ngsges M B H F Star Biotechnol Sintetske imunoglobulinske domene z vezavnimi lastnostmi, konstruiranimi v regijah molekule, različnih od regij, ki določajo komplementarnost
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
DK2158220T3 (en) 2007-06-26 2017-07-10 F-Star Biotechnologische Forschungs- Und Entw M B H Display of binders
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2016162505A1 (en) * 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
WO2017220555A1 (en) 2016-06-20 2017-12-28 F-Star Beta Limited Lag -3 binding members
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3497128A2 (en) 2016-08-09 2019-06-19 Kymab Limited Anti-icos antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
EP3728314A1 (en) * 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
CN107868814A (zh) * 2017-12-19 2018-04-03 威海威仕泰医疗科技有限公司 一种用于检测HER2基因的Dig标记探针的制备方法
SG11202009625WA (en) * 2018-04-02 2020-10-29 Bristol Myers Squibb Co Anti-trem-1 antibodies and uses thereof
EP3793604A4 (en) * 2018-05-17 2022-03-02 Immunome, Inc. Ch3 domain epitope tags
CN108875302B (zh) * 2018-06-22 2022-02-22 广州漫瑞生物信息技术有限公司 一种检测细胞游离肿瘤基因拷贝数变异的系统和方法
CA3106048A1 (en) 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind cd137 and ox40
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
KR102325731B1 (ko) * 2020-01-15 2021-11-15 주식회사 베르티스 암의 진단용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1699826T1 (sl) * 2005-01-05 2009-08-31 Ngsges M B H F Star Biotechnol Sintetske imunoglobulinske domene z vezavnimi lastnostmi, konstruiranimi v regijah molekule, različnih od regij, ki določajo komplementarnost
DK2158220T3 (en) * 2007-06-26 2017-07-10 F-Star Biotechnologische Forschungs- Und Entw M B H Display of binders
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US20120121586A1 (en) * 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody

Also Published As

Publication number Publication date
AU2014330942A1 (en) 2016-05-19
SG11201602605TA (en) 2016-04-28
ES2687783T3 (es) 2018-10-29
HRP20181566T1 (hr) 2018-11-30
HK1221746A1 (zh) 2017-06-09
CN105722997A (zh) 2016-06-29
EP3052647A1 (en) 2016-08-10
EP3052647B1 (en) 2018-07-11
DK3052647T3 (en) 2018-10-22
KR20160092992A (ko) 2016-08-05
EA201690450A1 (ru) 2016-10-31
PE20160950A1 (es) 2016-10-02
IL244510A0 (en) 2016-04-21
GB201317622D0 (en) 2013-11-20
US20160289336A1 (en) 2016-10-06
BR112016007348A2 (pt) 2018-01-23
JP2016533395A (ja) 2016-10-27
WO2015049537A1 (en) 2015-04-09
JP6449308B2 (ja) 2019-01-09
MX2016004286A (es) 2017-01-18
LT3052647T (lt) 2018-10-25
CA2925186A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
CL2016000777A1 (es) Biomarcadores de cáncer y usos de los mismos
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
BR112015025408A2 (pt) combinações de droga para tratar câncer
DK3077047T3 (da) Aramcholsalte
DK2956698T3 (da) Bindestrimler
DK3071675T3 (da) Kombineret energinet
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
EP2952513A4 (en) AZOLE AND BENZENE DERIVATIVE
DK3052081T3 (da) Pastil
DK2946640T3 (da) Langmuir-probe
CL2016001382A1 (es) Estabilidad de gel mejorada
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DE112014005606A5 (de) CVT-Getriebe
PT3013706T (pt) Difusor
DE102013106534B8 (de) Chromatographiepipettenspitze
DK3071227T3 (da) Fiskevaccine
HK1216391A1 (zh) 組合治療
DK3051953T3 (da) Varmluft-stativovn
DK2981168T3 (da) Laminitiskile
DK3086679T3 (da) Sportssko
DE112014005595A5 (de) CVT-Getriebe
ITFR20130011U1 (it) Tombino antiallagamento